{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T07:29:05Z","timestamp":1726471745217},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.diagmicrobio.2009.10.018","type":"journal-article","created":{"date-parts":[[2009,12,18]],"date-time":"2009-12-18T15:30:41Z","timestamp":1261150241000},"page":"308-313","source":"Crossref","is-referenced-by-count":11,"title":["Susceptibility to tigecycline of isolates from samples collected in hospitalized patients with secondary peritonitis undergoing surgery"],"prefix":"10.1016","volume":"66","author":[{"given":"Fe","family":"Tubau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josefina","family":"Li\u00f1ares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria-Dolores","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilia","family":"Cercenado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria-Jose","family":"Aldea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Gonz\u00e1lez-Romo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Torroba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Berdonces","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaquin","family":"Plazas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Garc\u00eda-Escribano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 5","key":"10.1016\/j.diagmicrobio.2009.10.018_bib1","doi-asserted-by":"crossref","first-page":"S354","DOI":"10.1086\/431676","article-title":"The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data","volume":"41","author":"Babinchak","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2009.10.018_bib2","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1128\/JCM.00089-07","article-title":"Validation and reproducibility assessment of tigecycline MIC determinations by Etest","volume":"45","author":"Bolmstr\u00f6m","year":"2007","journal-title":"J. Clin. Microbiol."},{"author":"British Society for Antimicrobial Chemotherapy","key":"10.1016\/j.diagmicrobio.2009.10.018_bib3"},{"issue":"Espec Congr","key":"10.1016\/j.diagmicrobio.2009.10.018_bib4","first-page":"58","article-title":"Actividad in vitro de tigeciclina frente Acinetobacter baumannii: variaciones de CMIs por E-test dependientes del tipo de medio Mueller\u2013Hinton II utilizado en rutina","volume":"25","author":"Camarena","year":"2007","journal-title":"Enferm. Infect. Microbiol. Clin."},{"key":"10.1016\/j.diagmicrobio.2009.10.018_bib5","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/jac\/dkp169","article-title":"Influence of testing methodology on the tigecycline activity profile against presumably tigecycline-non-susceptible Acinetobacter spp","volume":"64","author":"Casal","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"year":"2007","series-title":"Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard\u2014seventh edition, M11-A7","author":"Clinical and Laboratory Standards Institute (CLSI)","key":"10.1016\/j.diagmicrobio.2009.10.018_bib6"},{"year":"2007","series-title":"Performance standards for antimicrobial susceptibility testing: 70th informational supplement (M100-S17)","author":"Clinical and Laboratory Standards Institute (CLSI)","key":"10.1016\/j.diagmicrobio.2009.10.018_bib7"},{"author":"European Committee on Antimicrobial Susceptibility Testing","key":"10.1016\/j.diagmicrobio.2009.10.018_bib8"},{"key":"10.1016\/j.diagmicrobio.2009.10.018_bib9","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1128\/JCM.02464-08","article-title":"High concentrations of manganese in Mueller\u2013Hinton agar increase MICs of tigecycline determined by Etest","volume":"47","author":"Fern\u00e1ndez-Mazarrasa","year":"2009","journal-title":"J. Clin. Microbiol."},{"author":"Food and Drug Administration","key":"10.1016\/j.diagmicrobio.2009.10.018_bib10"},{"key":"10.1016\/j.diagmicrobio.2009.10.018_bib11","first-page":"387","article-title":"Therapeutic efficacy, animal models and experimental pharmacodynamics: what do we know about tigecycline? [Article in Spanish]","volume":"20","author":"Gim\u00e9nez","year":"2007","journal-title":"Rev. Esp. Quimioterap."},{"key":"10.1016\/j.diagmicrobio.2009.10.018_bib12","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.diagmicrobio.2005.05.006","article-title":"Pharmacokinetic\/pharmacodynamic profile for tigecycline\u2014a new glycylcycline antimicrobial agent","volume":"52","author":"Meagher","year":"2005","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2009.10.018_bib13","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/jac\/dkp005","article-title":"Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: results of the French prospective, observational EBIIA study","volume":"63","author":"Montravers","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.10.018_bib14","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1128\/AAC.49.1.220-229.2005","article-title":"Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects","volume":"49","author":"Muralidharan","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.10.018_bib15","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1471-2334-5-88","article-title":"A multicenter trial of the efficacy and safety of tigecycline versus imipenem\/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]","volume":"5","author":"Oliva","year":"2005","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2009.10.018_bib16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1075-9964(03)00117-3","article-title":"Assessment of tigecycline (GAR-936) efficacy in a rat model for intra-abdominal sepsis. Abstracts of 3rd World Congress on Anaerobic Bacteria and Infections","volume":"9","author":"Onderdonk","year":"2003","journal-title":"Anaerobe"},{"key":"10.1016\/j.diagmicrobio.2009.10.018_bib17","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1128\/AAC.00813-07","article-title":"Exposure-response analyses of tigecycline efficacy in patients with complicated intraabdominal infections","volume":"52","author":"Passarell","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.10.018_bib18","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1128\/JCM.00637-08","article-title":"In vitro activity of tigecycline against gram-positive and gram-negative pathogens as evaluated by broth microdilution and Etest","volume":"46","author":"Pillar","year":"2008","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2009.10.018_bib19","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/jac\/dkl403","article-title":"Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose","volume":"58","author":"Rodvold","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.10.018_bib20","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1128\/AAC.44.4.943-949.2000","article-title":"In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria","volume":"44","author":"Van Ogtrop","year":"2000","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073288930900443X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073288930900443X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T12:53:15Z","timestamp":1544791995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073288930900443X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S073288930900443X"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2009.10.018","relation":{},"ISSN":["0732-8893"],"issn-type":[{"type":"print","value":"0732-8893"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}